Literature DB >> 10052994

CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs.

H K Han1, J K Rhie, D M Oh, G Saito, C P Hsu, B H Stewart, G L Amidon.   

Abstract

The present study characterized Chinese hamster ovary cells overexpressing a human intestinal peptide transporter, CHO/hPEPT1 cells, as an in vitro model for peptidomimetic drugs. The kinetic parameters of Gly-Sar uptake were determined in three different cell culture systems such as untransfected CHO cells (CHO-K1), transfected CHO cells (CHO/hPEPT1) and Caco-2 cells. Vmax in CHO/hPEPT1 cells was approximately 3-fold higher than those in Caco-2 cells and CHO-K1 cells, while Km values were similar in all cases. The uptake of beta-lactam antibiotics in CHO/hPEPT1 cells was three to twelve fold higher than that in CHO-K1 cells, indicating that CHO/hPEPT1 cells significantly enhanced the peptide transport activity. However, amino acid drugs also exhibited high cellular uptake in both CHO-K1 and CHO/hPEPT1 cells due to the high background level of amino acid transporters. Thus, cellular uptake study in CHO/hPEPT1 cells is not sensitive enough to distinguish the peptidyl drugs from amino acid drugs. The potential of CHO/hPEPT1 cells as an in vitro model for peptidomimetic drugs was also examined through the inhibition study on Gly-Sar uptake. Peptidomimetic drugs such as beta-lactam antibiotics and enalapril significantly inhibited Gly-Sar uptake whereas the nonpeptidyl compounds, L-dopa and alpha-methyldopa, did not compete with Gly-Sar for cellular uptake within the therapeutic concentrations. In conclusion, the present study demonstrates the further characterization of CHO/hPEPT1 cells as an uptake model as well as inhibition study and suggests their utility as an alternative in vitro model for drug candidates targeting the hPEPT1 transporter.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10052994     DOI: 10.1021/js980132e

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs.

Authors:  Duxin Sun; Hans Lennernas; Lynda S Welage; Jeffery L Barnett; Christopher P Landowski; David Foster; David Fleisher; Kyung-Dall Lee; Gordon L Amidon
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

Review 2.  Pharmacophore-based discovery of ligands for drug transporters.

Authors:  Cheng Chang; Sean Ekins; Praveen Bahadduri; Peter W Swaan
Journal:  Adv Drug Deliv Rev       Date:  2006-09-26       Impact factor: 15.470

3.  Tumor necrosis factor-alpha and interferon-gamma increase PepT1 expression and activity in the human colon carcinoma cell line Caco-2/bbe and in mouse intestine.

Authors:  Stephan R Vavricka; Mark W Musch; Mikihiro Fujiya; Keri Kles; Laura Chang; Jyrki J Eloranta; Gerd A Kullak-Ublick; Ken Drabik; Didier Merlin; Eugene B Chang
Journal:  Pflugers Arch       Date:  2005-11-19       Impact factor: 3.657

4.  Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements.

Authors:  Caroline A Larregieu; Leslie Z Benet
Journal:  AAPS J       Date:  2013-01-24       Impact factor: 4.009

5.  In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors.

Authors:  Sean Ekins; Jeffrey S Johnston; Praveen Bahadduri; Vanessa M D'Souza; Abhijit Ray; Cheng Chang; Peter W Swaan
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

6.  Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine.

Authors:  Michael Pennick
Journal:  Neuropsychiatr Dis Treat       Date:  2010-06-24       Impact factor: 2.570

7.  In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1.

Authors:  Y Anne Pak; Amanda J Long; William F Annes; Jennifer W Witcher; Mary Pat Knadler; Mosun A Ayan-Oshodi; Malcolm I Mitchell; Phillip Leese; Kathleen M Hillgren
Journal:  Drug Metab Dispos       Date:  2016-11-28       Impact factor: 3.922

8.  Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development.

Authors:  Omri Wolk; Riad Agbaria; Arik Dahan
Journal:  Drug Des Devel Ther       Date:  2014-09-24       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.